Clinical Trials Using Anti-TIGIT Monoclonal Antibody BMS-986207

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-TIGIT Monoclonal Antibody BMS-986207. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

    This a Phase I / II randomized trial for patients with relapsed refractory Multiple Myeloma who have relapsed after treatment with prior therapies. The protocol is designed to evaluate two agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic effects and safety both as single agents and in combination with pomalidomide and dexamethasone. In these arms, patients will be treated with either Anti-LAG-3 or Anti-TIGIT respectively for one cycle as single agent followed by the addition of pomalidomide and dexamethasone in combination for subsequent cycles. A third arm allows patients to be treated with the FDA approved combination of elotuzumab plus pomalidomide and dexamethsone as a control. This arm will thus allow a concurrent standard of care comparator for the experimental arms.
    Location: 4 locations

  • COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

    This is a phase 1 / 2 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM701 in combination with BMS-986207 and nivolumab in patients with advanced solid tumors.
    Location: 3 locations